

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **THE GROUP'S PRODUCT AMOXICILLIN SODIUM AND CLAVULANATE POTASSIUM FOR INJECTION PASSED THE CONSISTENCY EVALUATION**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that Amoxicillin Sodium and Clavulanate Potassium for Injection (specifications: 0.6g; 1.2g) submitted by Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, a wholly-owned subsidiary of the Company, has been approved by China National Medical Products Administration, passed the consistency evaluation of quality and efficacy for generic drugs ("Consistency Evaluation").

Amoxicillin Sodium and Clavulanate Potassium for Injection is a broad-spectrum penicillin antibiotic composed of amoxicillin sodium (a penicillin antibiotic) and potassium clavulanate (a  $\beta$ -lactamase inhibitor). Clavulanic acid enhances the antibacterial activity of amoxicillin against resistant bacteria by inhibiting  $\beta$ -lactamase enzymes produced by certain bacteria. It is clinically indicated for the treatment of infections caused by susceptible bacteria, including upper and lower respiratory tract infections, genitourinary tract infections, skin and soft tissue infections, and bone and joint infections. Currently, Amoxicillin Sodium and Clavulanate Potassium for Injection is listed in the National Essential Drug List (2018 edition) and is classified as a Category B drug in the National Medical Insurance Drug List (2024 edition).

This approval will further solidify the Company's leading position in the anti-infective field. In the future, the Company will continue to devote itself to the research and development of new products and the promotion of the Consistency Evaluation, which is expected to create greater values for the Company and its shareholders.

By Order of the Board  
**The United Laboratories International Holdings Limited**  
**Tsoi Hoi Shan**  
*Chairman*

Hong Kong, 17 July 2025

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.